On 27 October, FDA/CBER issued draft guidance proposing that an individualised genome-editing product with multiple variants could be licensed under a single section 351(a) BLA. The draft covers how permitted variation is defined, how new variants are added after licensure, and how potency, safety and process validation are shown across the product family. Two days later, FDA’s Office of Combination Products, with CDER, CBER and CDRH, published draft guidance on the drug-delivery performance characteristics that must be established for autoinjectors, pens, pumps, inhalers and connected delivery devices, for investigational, marketing and post-market change applications. Both drafts are non-binding and both focus on how controlled change is managed after approval, with comments due by 27 November 2026 (genome editing) and 28 January 2027 (drug delivery).
Change-control models built for static commercial products will not hold up for therapies where variation is built in, or where a software or component change can alter the dose delivered. Quality systems must now show exactly which evidence supports the whole platform and which must be generated for each variant or change.
Commission a gap assessment before the comment windows close. It should separate platform-wide from variant-specific CQAs and trace the essential delivery characteristics through design inputs, risk files and post-approval change triggers.